Get startedLog in
    Picture of NRC Health logo

    NRC — NRC Health News Story

    0.000.00%
    us flag iconLast trade - 00:00
    Consumer CyclicalsAdventurousMid CapHigh Flyer
    All News

    Brief: National Research Q2 Adjusted EPS USD 0.28

    Picture of NRC Health logoNRC Health
    28/07/2025 22:00
    Overview

NRC Q2 TRCV grows 2% sequentially, marking third consecutive quarter of growth

Adjusted EBITDA margin stable at 30% despite non-recurring executive compensation

Company repurchased 381,736 shares, returning $16.1 mln to shareholders

Result Drivers

TRCV GROWTH - 2% sequential increase in TRCV, driven by improved new logo sales, cross-sells, and customer retention

SALES TEAM STRENGTH - Stronger sales team and resonating product portfolio credited for improved customer retention

COST CONTROL - Adjusted EBITDA margin stable at 30% due to cost control initiatives and higher revenue per FTE

Key Details


    MetricBeat/MissActualConsensus Estimate
    Q2 Revenue$34.04 mln
    Q2 Adjusted EPS$0.28
    Q2 EPS-$0.01
    Q2 Net Income-$106,000
    

Press Release: ID:nBw4xvdWfa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

    Recent news on NRC Health

    See all news